2023
Interventional Radiology and Surgical Treatment Options for Non-Cirrhotic Portal Hypertension
Rabiee A, Cornman-Homonoff J, Kunstman J, Garcia-Tsao G, Taddei T. Interventional Radiology and Surgical Treatment Options for Non-Cirrhotic Portal Hypertension. Current Hepatology Reports 2023, 22: 269-275. DOI: 10.1007/s11901-023-00617-4.Peer-Reviewed Original ResearchPortal hypertensionInterventional radiologyNon-cirrhotic portal hypertensionPorto-sinusoidal vascular diseaseHepatic sinusoidal obstruction syndromeAbsence of cirrhosisPortal vein thrombosisSinusoidal obstruction syndromeBudd-Chiari syndromeSurgical treatment optionsHepatic vascular anatomyObstruction syndromeVein thrombosisSurgical treatmentTreatment optionsVascular diseaseImproved outcomesTherapeutic evaluationVascular anatomyHeterogenous groupHypertensionSyndromeDisordersOutcomesTreatmentAASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis
Kaplan D, Ripoll C, Thiele M, Fortune B, Simonetto D, Garcia-Tsao G, Bosch J. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2023, 79: 1180-1211. PMID: 37870298, DOI: 10.1097/hep.0000000000000647.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2022
Endovascular Assessment of Liver Hemodynamics in Patients with Cirrhosis Complicated by Portal Hypertension
Ferral H, Schepis F, Gaba R, Garcia-Tsao G, Zanetto A, Perez-Campuzano V, Haskal Z, Garcia-Pagan J. Endovascular Assessment of Liver Hemodynamics in Patients with Cirrhosis Complicated by Portal Hypertension. Journal Of Vascular And Interventional Radiology 2022, 34: 327-336. PMID: 36516940, DOI: 10.1016/j.jvir.2022.12.014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHepatic venous pressure gradientPortal hypertensionPortosystemic pressure gradientTransjugular intrahepatic portosystemic shuntVenous pressure gradientIntrahepatic portosystemic shuntSurgical patientsRisk stratificationHemodynamic measurementsPortosystemic shuntLiver hemodynamicsTreatment optionsShunt diameterMeticulous techniquePatientsClinical practiceGold standardHypertensionManagement optionsPressure gradientCirrhosisComplicatedHemodynamicsOptionsShunt
2021
Baveno VII – Renewing consensus in portal hypertension
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Faculty B, Abraldes J, Albillos A, Baiges A, Bajaj J, Bañares R, Barrufet M, Benajiba L, Berzigotti A, Bureau C, Calvaruso V, Cardenas A, D’Amico G, De Gottardi A, Dell’Era A, Escorsell A, Fallowfield J, Ferral H, Francque S, Gaba R, Garcia-Pagàn J, Genescà J, Rodrigues S, Gracia-Sancho J, Han G, Hernandez-Gea V, Jia J, Kiladjian J, Krag A, Laleman W, La Mura V, Lens S, Luo X, Mandorfer M, Murad S, Paradis V, Patch D, Piano S, Pinzani M, Plessier A, Primignani M, Procopet B, Rautou P, Rudler M, Sarin S, Schepis F, Senzolo M, Shah V, Shukla A, Tandon P, Tellez L, Thabut D, Thiele M, Trebicka J, Tripathi D, Tsochatzis E, Turco L, Turon F, Valla D, Villanueva C, Wanless I, Yoshiji H. Baveno VII – Renewing consensus in portal hypertension. Journal Of Hepatology 2021, 76: 959-974. PMID: 35120736, PMCID: PMC11090185, DOI: 10.1016/j.jhep.2021.12.022.Peer-Reviewed Original ResearchConceptsPortal hypertensionAdvanced chronic liver diseaseHepatic venous pressure gradientAcute bleeding episodeSignificant portal hypertensionVenous pressure gradientChronic liver diseaseSplanchnic vein thrombosisCourse of cirrhosisRisk of deathNon-invasive toolBleeding episodesCompensated cirrhosisFurther decompensationVein thrombosisLiver diseaseBaveno VIVascular disordersFirst episodeHypertensionPersonalized careMedical literatureTherapeutic needsGold standardCirrhosis
2020
SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension
Saffo S, Garcia‐Tsao G, Taddei T. SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension. Journal Of Diabetes 2020, 13: 265-269. PMID: 33210815, DOI: 10.1111/1753-0407.13136.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBenzhydryl CompoundsCohort StudiesDiabetes Mellitus, Type 2FemaleGlucosidesGlycated HemoglobinHumansHypertension, PortalLiver CirrhosisMaleMiddle AgedOutcome Assessment, Health CarePolyuriaSodium-Glucose Transporter 2 InhibitorsTertiary Care CentersUrinary Tract InfectionsYoung AdultConceptsSGLT2 inhibitorsPortal hypertensionDiabetes mellitusSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsCenter cohort studyCotransporter 2 inhibitorsCohort of patientsPotential therapeutic targetFavorable pleiotropic effectsCohort studyRenal diseaseClinical trialsClinical dataTherapeutic targetPatientsCirrhosisHypertensionMellitusOngoing evaluationInhibitorsPleiotropic effectsCohortDiseaseTrialsSu1696 SPLEEN STIFFNESS MEASUREMENTS (SSM) IN THE IDENTIFICATION OF CLINICALLY-SIGNIFICANT PORTAL HYPERTENSION (CSPH) IN PATIENTS WITH COMPENSATED CIRRHOSIS.
Ortiz G, Palumbo C, Sayyar M, Balakrishnan M, Mohanty A, Garcia-Tsao G. Su1696 SPLEEN STIFFNESS MEASUREMENTS (SSM) IN THE IDENTIFICATION OF CLINICALLY-SIGNIFICANT PORTAL HYPERTENSION (CSPH) IN PATIENTS WITH COMPENSATED CIRRHOSIS. Gastroenterology 2020, 158: s-1385. DOI: 10.1016/s0016-5085(20)34131-7.Peer-Reviewed Original Research
2019
LBO-01-Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension
Garcia-Tsao G, Bosch J, Kayali Z, Harrison S, Abdelmalek M, Lawitz E, Satapathy S, Ghabril M, Shiffman M, Younes Z, Thuluvath P, Berzigotti A, Albillos A, Robinson J, Chan J, Hagerty D, Sanyal A. LBO-01-Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension. Journal Of Hepatology 2019, 70: e127. DOI: 10.1016/s0618-8278(19)30225-7.Peer-Reviewed Original Research
2018
LBO-001 A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension
Chalasani N, Garcia-Tsao G, Goodman Z, Lawitz E, Abdelmalek M, Rinella M, Ryan M, Noureddin M, Jue C, Pyko M, Allgood A, Shlevin H, Horton R, Zomer E, Traber P, Loomba R, Tetri B, Sanyal A, Harrison S. LBO-001 A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension. Journal Of Hepatology 2018, 68: s100-s101. DOI: 10.1016/s0168-8278(18)30420-3.Peer-Reviewed Original ResearchCirrhosis and Portal Hypertension: Staging and Prognosis
Garcia-Tsao G. Cirrhosis and Portal Hypertension: Staging and Prognosis. 2018, 1-13. DOI: 10.1007/978-3-319-72628-1_1.Peer-Reviewed Educational MaterialsSignificant portal hypertensionPortal hypertensionDecompensated stagePredominant pathophysiological mechanismPresence of varicesGastroesophageal varicesPrognostic significanceReversible diseasePathophysiological mechanismsDifferent therapiesHypertensionVaricesCirrhosisDecompensationPatientsTherapyDisease
2017
Management of Portal Hypertension
Garcia‐Tsao G, Abraldes J. Management of Portal Hypertension. 2017, 304-335. DOI: 10.1002/9781119251316.ch12.Peer-Reviewed Educational MaterialsComplications of cirrhosisPortal hypertensionVariceal hemorrhagePortal pressure gradientInferior vena cavaObjective of treatmentGastroesophageal varicesPortal pressurePathological increaseVena cavaPortal veinCommon causeCirrhosisHypertensionComplicationsHemorrhageMost studiesVaricesDecompensationCavaLBP-516 13C-Methacetin Breath Test accurately assesses clinically significant portal hypertension in patients with NASH cirrhosis
Ilan Y, Harrison S, Traber P, Chalasani N, Garcia-Tsao G. LBP-516 13C-Methacetin Breath Test accurately assesses clinically significant portal hypertension in patients with NASH cirrhosis. Journal Of Hepatology 2017, 66: s100. DOI: 10.1016/s0168-8278(17)30461-0.Peer-Reviewed Original ResearchChapter 36 Ascites
Garcia-Tsao G. Chapter 36 Ascites. 2017, 475-484. DOI: 10.1016/b978-0-12-804274-8.00036-9.Peer-Reviewed Educational MaterialsRefractory ascitesCommon decompensating eventNew-onset ascitesSodium-retaining systemsFirst-line therapyDevelopment of ascitesCause of deathPortal hypertensionRenal failureSodium retentionPathophysiological mechanismsOvert infectionAscitesPathogenic cascadeHigh mortalityVasodilatationEarly placementPatientsCirrhosisDeathHypertensionTherapyInfectionMortality
2014
Prognostic Factors in Compensated and Decompensated Cirrhosis
Ripoll C, Zipprich A, Garcia-Tsao G. Prognostic Factors in Compensated and Decompensated Cirrhosis. Current Hepatology Reports 2014, 13: 171-179. DOI: 10.1007/s11901-014-0234-6.Peer-Reviewed Original ResearchHepatic venous pressure gradientPortal hypertensionPredictive factorsSignificant portal hypertensionSpecific predictive factorsVenous pressure gradientSerum albumin levelAlternative non-invasive methodDecompensated diseaseMELD scoreClinical decompensationFurther decompensationAlbumin levelsPrognostic factorsNon-invasive methodCirrhosisInvasive proceduresDecompensationDeathHypertensionNumber of studiesImportant predictorChildren's scoresRecent studiesScores
2012
Quantitative histological‐hemodynamic correlations in cirrhosis
Sethasine S, Jain D, Groszmann RJ, Garcia‐Tsao G. Quantitative histological‐hemodynamic correlations in cirrhosis. Hepatology 2012, 55: 1146-1153. PMID: 22109744, PMCID: PMC3721182, DOI: 10.1002/hep.24805.Peer-Reviewed Original ResearchConceptsSignificant portal hypertensionPortal hypertensionFibrosis areaLiver biopsyCirrhotic nodulesNodule sizeHVPG measurementPortal pressureIndependent predictorsSeptal thicknessFibrous septaBiopsyPathophysiological implicationsCirrhosisHVPGPatientsSemiquantitative analysisNodulesOnly parameterHypertensionNumber of nodules
2011
Management: Cirrhotic Portal Hypertension
Lim J, Garcia-Tsao G. Management: Cirrhotic Portal Hypertension. 2011, 165-181. DOI: 10.1007/978-1-4419-8327-5_11.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPortal hypertensionVariceal hemorrhageAcute variceal hemorrhageCirrhotic portal hypertensionBetter risk stratificationNovel pharmacotherapeutic agentsGastroesophageal varicesPortal pressureRisk stratificationMain complicationsNoninvasive markerPharmacotherapeutic agentsIndividualized careHypertensionVaricesHemorrhageSignificant mortalityCirrhosisSignificant improvementProphylaxisComplicationsPatientsRecurrenceMortality
2009
Erratum: Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program
Garcia-Tsao G, Lim J. Erratum: Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. The American Journal Of Gastroenterology 2009, 104: ajg2009360. DOI: 10.1038/ajg.2009.360.Commentaries, Editorials and Letters
2008
Portal hypertension and variceal bleeding—Unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single‐topic conference
Garcia‐Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding—Unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single‐topic conference. Hepatology 2008, 47: 1764-1772. PMID: 18435460, DOI: 10.1002/hep.22273.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2007
Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis
Qamar AA, Grace ND, Groszmann RJ, Garcia‐Tsao G, Bosch J, Burroughs AK, Maurer R, Planas R, Escorsell A, Garcia‐Pagan J, Patch D, Matloff DS, Makuch R, Group P. Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. Hepatology 2007, 47: 153-159. PMID: 18161700, DOI: 10.1002/hep.21941.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientPresence of GEVsGastroesophageal varicesPlatelet countPortal hypertensionMild portal hypertensionSpecific platelet countDouble-blind trialVenous pressure gradientTime of endoscopyHVPG changesCompensated cirrhosisHVPG measurementNoninvasive testsCurrent guidelinesNoninvasive markerPatientsSecondary analysisLongitudinal evaluationCirrhosisEsophagogastroduodenoscopyHypertensionVaricesPresent longitudinal studyLongitudinal studyHepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis
Ripoll C, Groszmann R, Garcia–Tsao G, Grace N, Burroughs A, Planas R, Escorsell A, Garcia–Pagan J, Makuch R, Patch D, Matloff DS, Bosch J, Group P. Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis. Gastroenterology 2007, 133: 481-488. PMID: 17681169, DOI: 10.1053/j.gastro.2007.05.024.Peer-Reviewed Original ResearchMeSH KeywordsAgedAscitesEsophageal and Gastric VaricesFemaleFollow-Up StudiesGastrointestinal HemorrhageHepatic EncephalopathyHumansHypertension, PortalKaplan-Meier EstimateLiver CirrhosisMaleMiddle AgedPortal PressurePredictive Value of TestsPrognosisProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsROC CurveSensitivity and SpecificitySeverity of Illness IndexTime FactorsConceptsHepatic venous pressure gradientVenous pressure gradientClinical decompensationPortal hypertensionMedian hepatic venous pressure gradientEnd-stage liver diseaseDiagnostic capacityBaseline laboratory testsPredictors of decompensationChild-Pugh scoreDevelopment of varicesMedical record reviewEnd of studyMedian followCompensated cirrhosisLiver transplantationLiver diseaseRecord reviewStudy terminationDecompensationPatientsCirrhosisMultivariate analysisVaricesHypertension
2006
Portal hypertension
Garcia-Tsao G. Portal hypertension. Current Opinion In Internal Medicine 2006, 5: 399-407. DOI: 10.1097/01.mog.0000218962.93806.9a.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPortal hypertensionVariceal bleedingTransjugular intrahepatic portosystemic shuntRecurrent variceal bleedingLarge-volume paracentesisSpontaneous bacterial peritonitisEndoscopic variceal ligationIntrahepatic portosystemic shuntHepatorenal syndromeRefractory ascitesBacterial peritonitisVariceal ligationSpecific complicationsPortosystemic shuntHypertensionΒ-blockersComplicationsTrialsBleedingVaricesAscitesDiagnosisRecent findingsRecent studiesCirrhosis